Retatrutide vs Tirzepatide: Triple Agonist vs Dual Agonist Compared
Medically reviewed by Medical Advisory Board Last reviewed 2026-07-21
More weight loss in trials, but only one of these is actually available today
Retatrutide (investigational triple GIP/GLP-1/glucagon agonist) has shown greater average weight loss than tirzepatide (Mounjaro/Zepbound, FDA-approved dual GIP/GLP-1 agonist) in trials, but only tirzepatide is currently available with a prescription.
This article is for informational purposes only and is not medical advice. Consult a physician for medical guidance.
Retatrutide and tirzepatide are frequently compared because both come from Eli Lilly and both build on the same GIP/GLP-1 receptor strategy — retatrutide simply adds a third receptor target (glucagon) to the mix. The trial numbers for retatrutide are genuinely impressive, which is why search interest has grown quickly, but the practical comparison has to account for the fact that only tirzepatide is FDA-approved and prescribable today. For background on each compound individually, see our guides to retatrutide and GLP-1 peptides, and our existing comparison of Mounjaro vs Zepbound (both brand names for tirzepatide). If you're weighing retatrutide against the single-receptor option instead, see our retatrutide vs semaglutide comparison.
Want expert help with your metabolic health?
We can match you with a metabolic-medicine specialist who understands this area — so you get the right doctor, not just any doctor.
Book An Appointment With A Specialist →Retatrutide vs Tirzepatide: Side-by-Side
| Factor | Retatrutide | Tirzepatide (Mounjaro/Zepbound) |
|---|---|---|
| Receptors targeted | GIP + GLP-1 + glucagon (triple agonist) | GIP + GLP-1 (dual agonist) |
| FDA status | Investigational — in Phase 3 trials | FDA-approved (Mounjaro for type 2 diabetes; Zepbound for weight management) |
| Trial weight loss | Up to 24.2% mean body weight at 48 weeks (Phase 2) | Up to 22.5% mean body weight at 72 weeks (SURMOUNT-1) |
| Availability | Not available outside clinical trials | Available by prescription; compounded versions also exist where legal |
| Cost | N/A (not commercially available) | $1,000-$1,300/month list price (brand); often less with insurance or compounding |
| Common side effects | GI symptoms (nausea, diarrhea, vomiting, constipation), dose-related | Similar GI symptom profile, well-characterized from years of use |
| Safety data volume | Limited — Phase 2/3 trial populations only | Extensive — years of post-marketing surveillance |
Why Retatrutide Shows More Weight Loss in Trials
Tirzepatide's dual mechanism already outperforms single-target GLP-1 drugs like semaglutide by adding GIP receptor activation, which appears to have a synergistic fat-mobilizing effect. Retatrutide goes a step further by adding glucagon receptor activation, which increases energy expenditure on top of the appetite suppression and improved insulin sensitivity shared with GLP-1/GIP drugs. In Lilly's Phase 2 obesity trial, the highest retatrutide dose produced a mean 24.2% body-weight reduction at 48 weeks — meaningfully higher than tirzepatide's Phase 3 results, though the two haven't been directly compared head-to-head in the same trial.
Why Tirzepatide Is the Practical Choice Today
The core issue is availability: tirzepatide has an FDA-approved label, years of real-world prescribing experience, and established monitoring practices. Retatrutide remains investigational — it cannot be legally prescribed for weight loss or diabetes outside a clinical trial, and any product sold online claiming to be retatrutide for personal use carries serious sourcing and safety risks (unverified purity, concentration, and sterility). Choosing based on trial headlines alone ignores that one option is a real, monitored prescription and the other, for now, is not.
What to Do If You're Considering Either
- If you want treatment now: tirzepatide (Mounjaro or Zepbound, depending on your diagnosis) is the available, FDA-approved option with an established safety record.
- If you're waiting on retatrutide: Phase 3 trials are ongoing; FDA review and approval timelines for genuinely new drugs typically take a year or more after trials complete. There's no reliable way to access authentic retatrutide safely outside a clinical trial in the meantime.
- Do not buy "research retatrutide" for self-injection. Unregulated vials carry real risks around purity, dosing accuracy, and sterility.
Take the free assessment to review whether appetite, insulin resistance, or another metabolic factor is the better starting point for your weight-loss plan while you wait on newer options. For the full three-way picture including semaglutide, see our semaglutide vs tirzepatide vs retatrutide comparison.
What to Look For in a Body-Composition Scale
A bioimpedance scale trends body fat and muscle rather than just weight — useful when the number stalls but your composition is improving. The absolute body-fat % isn't lab-accurate, so use it for TRENDS at a consistent time of day. Choose one that syncs to an app so you can watch the trend line.
Frequently Asked Questions
Is retatrutide better than tirzepatide?
In Phase 2 trial data, retatrutide produced greater average weight loss than tirzepatide's Phase 3 results, likely due to its added glucagon receptor activation. However, the two haven't been tested head-to-head in the same trial, and retatrutide isn't FDA-approved or available for prescribing, so "better" currently only applies to trial data, not real-world access.
Can I get retatrutide instead of tirzepatide right now?
No. Retatrutide is investigational and only available through clinical trial enrollment. It cannot be legally prescribed for weight loss or diabetes. Products marketed online as retatrutide for personal purchase are not FDA-regulated and carry meaningful safety risks.
When will retatrutide be approved?
As of mid-2026, retatrutide is in Phase 3 trials. Drug approval timelines vary, but new obesity/diabetes drugs typically take a year or more after Phase 3 completion for FDA review. There's no confirmed approval date yet — check clinicaltrials.gov or Eli Lilly's investor communications for the current status.
Do retatrutide and tirzepatide have the same side effects?
Both share a similar GI side-effect profile — nausea, diarrhea, vomiting, and constipation, most pronounced during dose escalation — because both act on overlapping receptor pathways. Retatrutide's additional glucagon receptor activation is a mechanistic difference that trial investigators are watching closely as later-stage safety data accumulates, since long-term human data is still limited compared to tirzepatide's established record.
Topic updates
Get the weekly peptide roundup
Peptide therapy, GLP-1s, growth hormone peptides, healing peptides, safety notes, and comparison guides.
Check Where You Stand
Take our free health assessment to understand your metabolic, hormonal, and recovery risk factors — and get personalized recommendations.
Take the Free Assessment →Free · Takes 5 minutes · Instant results
Related Comparisons
-
Semaglutide vs Tirzepatide vs Retatrutide: Single, Dual, and Triple Hormone Agonists Compared
Semaglutide vs tirzepatide vs retatrutide: single, dual, and triple hormone agonists compared side by side.
-
Retatrutide vs Semaglutide: Investigational Triple Agonist vs FDA-approved GLP-1 Compared
Retatrutide vs semaglutide: investigational triple agonist vs FDA-approved single agonist, trial data compared.
-
AOD-9604 vs Tirzepatide: Research Peptide vs FDA-approved Weight Loss Drug
AOD-9604 vs tirzepatide: unproven research peptide vs FDA-approved GLP-1 weight-loss drug.
See more related comparisons
-
Retatrutide Peptide: Triple Agonist Weight-loss Research, Risks, and Status
Retatrutide peptide research: triple agonist mechanism, trial results, risks, and current availability.
Affiliate disclosure: The Metabolic Journal is reader-supported. Some links above are affiliate or referral links and we may earn a commission at no extra cost to you. As an Amazon Associate we earn from qualifying purchases. Products are chosen on the merits; commissions never influence what we recommend. This is general information, not medical advice — talk to your clinician before acting.